Literature DB >> 9111078

Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells. Purification and characterization of an engineered truncated form from the culture medium.

J Costa1, E Grabenhorst, M Nimtz, H S Conradt.   

Abstract

Stable BHK-21 cell lines were constructed expressing the Golgi membrane-bound form and two secretory forms of the human alpha1, 3/4-fucosyltransferase (amino acids 35-361 and 46-361). It was found that 40% of the enzyme activity synthesized by cells transfected with the Golgi form of the fucosyltransferase was constitutively secreted into the medium. The corresponding enzyme detected by Western blot had an apparent molecular mass similar to those of the truncated secretory forms. The secretory variant (amino acids 46-361) was purified by a single affinity-chromatography step on GDP-Fractogel resin with a 20% final recovery. The purified enzyme had a unique NH2 terminus and contained N-linked endo H sensitive carbohydrate chains at its two glycosylation sites. The fucosyltransferase transferred fucose to the O-4 position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides, and glycoproteins containing the type I Galbeta1-3GlcNAc motif. The acceptor oligosaccharide in bovine asialofetuin was identified as the Man-3 branched triantennary isomer with one Galbeta1-3GlcNAc. The type II motif Galbeta1-4GlcNAc in bi-, tri-, or tetraantennary neutral or alpha2-3/alpha2-6 sialylated oligosaccharides with or without N-acetyllactosamine repeats and in native glycoproteins were not modified. The soluble forms of fucosyltransferase III secreted by stably transfected cells may be used for in vitro synthesis of the Lewisa determinant on carbohydrates and glycoproteins, whereas Lewisx and sialyl-Lewisx structures cannot be synthesized.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111078     DOI: 10.1074/jbc.272.17.11613

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.

Authors:  E Grabenhorst; P Schlenke; S Pohl; M Nimtz; H S Conradt
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

2.  Localization, purification and specificity of the full-length membrane-bound form of human recombinant alpha 1,3/4-fucosyltransferase from BHK-21B cells.

Authors:  V L Sousa; M T Costa; A S Palma; F Enguita; J Costa
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

3.  In vitro alpha1-3 or alpha1-4 fucosylation of type I and II oligosaccharides with secreted forms of recombinant human fucosyltransferases III and VI.

Authors:  M Nimtz; E Grabenhorst; U Gambert; J Costa; V Wray; M Morr; J Thiem; H S Conradt
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

4.  Unravelling the biochemical basis of blood group ABO and Lewis antigenic specificity.

Authors:  W T Morgan; W M Watkins
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

5.  Aglycone structure influences alpha-fucosyltransferase III activity using N-acetyllactosamine glycoside acceptors.

Authors:  Y Miura; S Kim; J R Etchison; Y Ding; O Hindsgaul; H H Freeze
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

6.  Expression and characterization of recombinant human alpha-3/4-fucosyltransferase III from Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) cells using the baculovirus expression system.

Authors:  V A Morais; J Serpa; A S Palma; T Costa; L Maranga; J Costa
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

7.  Construction and characterization of stably transfected BHK-21 cells with human-type sialylation characteristic.

Authors:  P Schlenke; E Grabenhorst; M Nimtz; H S Conradt
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

8.  Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications.

Authors:  Friedrich-Christian Deuschle; Volker Morath; André Schiefner; Corinna Brandt; Simone Ballke; Sybille Reder; Katja Steiger; Markus Schwaiger; Wolfgang Weber; Arne Skerra
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.